Department of Anesthesia and Intensive Care, Children's Hospital, Helsinki University, Central Hospital, P,O B, 281 Stenbäckinkatu 11, FIN-00029 HUCS Helsinki, Finland.
BMC Anesthesiol. 2011 Oct 5;11:18. doi: 10.1186/1471-2253-11-18.
Levosimendan has pharmacologic and hemodynamic advantages over conventional intravenous inotropic agents. It has been used mainly as a rescue drug in the pediatric intensive care unit or in the operating room. We present the largest single-center experience of levosimendan in children.
Retrospective analysis of all children who received levosimendan infusions between July 5, 2001 and July 4, 2010 in a pediatric intensive care unit. The results of a questionnaire for physicians (anesthesiologist/intensivists, cardiologists and cardiac surgeons) concerning their clinical perceptions of levosimendan are evaluated
During the study period a total of 484 infusions were delivered to 293 patients 53% of whom were male. The median age of the patients was 0.4 years (4 hours-21.1 years) at the time of levosimendan administration. A majority of levosimendan infusions were administered to children who were undergoing cardiac surgery (72%), 14% to children with cardiomyopathy and 14% to children with cardiac failure. Eighty-nine out of the 293 patients (30.4%) received repeated doses of levosimendan (up to 11 infusions). The most common indication for the use of levosimendan (94%) was when the other inotropic agents were insufficient to maintain stable hemodynamics. Levosimendan was especially used in children with cardiomyopathy (100%) or with low cardiac output syndrome (94%). A majority (89%) of the respondents believed that levosimendan administration postponed the need for mechanical assist devices in some children with cardiomyopathy. Moreover, 44% of respondents thought that the mechanical support was totally avoided in some patients undergoing cardiac surgery after receiving levosimendan.
Levosimendan is widely used in our institution and many physicians believe that its use could decrease the need for mechanical support in children undergoing cardiac surgery or in children with decompensated heart failure. However, there is a lack of good empirical evidence in children to support this perception.
左西孟旦具有优于传统静脉正性肌力药物的药理学和血液动力学优势。它主要被用作儿科重症监护病房或手术室中的抢救药物。我们报告了左西孟旦在儿童中使用的最大单中心经验。
回顾性分析 2001 年 7 月 5 日至 2010 年 7 月 4 日期间在儿科重症监护病房接受左西孟旦输注的所有儿童的资料。评估了医生(麻醉师/重症监护医师、心脏病专家和心脏外科医生)对左西孟旦临床认识的问卷调查结果。
在研究期间,共向 293 名患者输注了 484 次左西孟旦,其中 53%为男性。接受左西孟旦治疗时,患者的中位年龄为 0.4 岁(4 小时-21.1 岁)。大多数左西孟旦输注是在接受心脏手术的儿童中进行的(72%),14%是在心肌病儿童中进行的,14%是在心力衰竭儿童中进行的。293 名患者中有 89 名(30.4%)接受了重复剂量的左西孟旦(多达 11 次输注)。使用左西孟旦的最常见指征(94%)是其他正性肌力药物不足以维持稳定的血液动力学。左西孟旦尤其用于心肌病儿童(100%)或低心输出综合征儿童(94%)。大多数(89%)受访者认为,在一些患有心肌病的儿童中,左西孟旦的给药可推迟对机械辅助设备的需求。此外,44%的受访者认为,在接受左西孟旦治疗后,一些接受心脏手术的患者完全避免了机械支持。
左西孟旦在我们的机构中广泛使用,许多医生认为,它的使用可以减少心脏手术或心力衰竭失代偿的儿童对机械支持的需求。然而,儿童中缺乏支持这一观点的良好经验证据。